Ryvu Therapeutics SA · GPW:RVU

Ryvu Therapeutics SA — Investor Presentation (May 2023)

44 slides from Ryvu Therapeutics SA's investor presentation, May 2023

  1. Slide 1: Targeted therapeutics at the forefront of oncology

    Slide 1: Targeted therapeutics at the forefront of oncology

    Targeted therapeutics at the forefront of oncology CORPORATE PRESENTATION May 2023

  2. Slide 2: Note on the presentation and forward-looking statements

    Slide 2: Note on the presentation and forward-looking statements

    Note on the presentation and forward-looking statements This document does not constitute a public offering in the meaning of the Regulation (EU) 2017/1129 of the European Parliament and of the Council, or any other offer or invitation to acquire any Company's securities, nor the incentive to submit

  3. Slide 3: Ryvu at a glance

    Slide 3: Ryvu at a glance

    Ryvu at a glance Clinical Pipeline Small Molecule Discovery Platform Fully Integrated Across Heme and Solid Tumors Novel Synthetic Lethality Targets Research Organization RVU120 Developing small molecule therapies which address high-value emerging targets Team ~150 scientists (with ~80 PhDs) Wholly

  4. Slide 4: Ryvu evolution to clinical-stage pipeline and innovative partnerships

    Slide 4: Ryvu evolution to clinical-stage pipeline and innovative partnerships

    Ryvu evolution to clinical-stage pipeline and innovative partnerships 2007 - 2019 2019 - 2022 Corporate Evolution SEL24 RVU120 Partnerships and Financing • Successfully completed • First patients dosed in • Immune modulation • 2007: Selvita, a hybrid model biotech company, Ph I in AML Ph I/II studie

  5. Slide 5: Team with a strong track record of clinical development and shareholder value creation

    Slide 5: Team with a strong track record of clinical development and shareholder value creation

    Team with a strong track record of clinical development and shareholder value creation PAWEL PRZEWIEZLIKOWSKI, MSc, MBA KRZYSZTOF BRZOZKA, Ph.D., MBA HENDRIK NOGAI, M.D. KAMIL SITARZ, Ph.D., MBA VATNAK VAT-HO, MBA CEO and Founder CSO CMO COO CBO PETER LITTLEWOOD, MSc MARTIN SWARBRICK, Ph.D. MATEUSZ

  6. Slide 6: Broad pipeline addressing emerging targets in oncology

    Slide 6: Broad pipeline addressing emerging targets in oncology

    Broad pipeline addressing emerging targets in oncology 6

  7. Slide 7: RVU120: First-in-Class CDK8/19 Inhibitor in Hematologic and Solid Tumor Malignancies

    Slide 7: RVU120: First-in-Class CDK8/19 Inhibitor in Hematologic and Solid Tumor Malignancies

    RVU120: First-in-Class CDK8/19 Inhibitor in Hematologic and Solid Tumor Malignancies

  8. Slide 8: RVU120: First-in-class CDK8/CDK19 inhibitor

    Slide 8: RVU120: First-in-class CDK8/CDK19 inhibitor

    RVU120: First-in-class CDK8/CDK19 inhibitor Mechanism of action applicable to hematologic and solid tumors CDK8/19 inhibition by RVU120 triggers CDK8/19 pathway promotes tumor growth differentiation and apoptosis Viability of tumor cells Apoptosis of tumor cells Maintenance of malignant stem cells A

  9. Slide 9: RVU120: Potential across a broad range of tumors

    Slide 9: RVU120: Potential across a broad range of tumors

    RVU120: Potential across a broad range of tumors Blood Cancers & Disorders Solid tumors Neuroendocrine AML Breast MDS JAK2 mut MPN Sarcoma NHL HCC Diamond-Blackfan Anemia Colorectal Prostate • Early signs of efficacy in AML/HR-MDS, • Preclinical evidence in TNBC including CR; Phase I update at ASH 2

  10. Slide 10: RVU120: Highly selective and potent inhibitor of CDK8/19

    Slide 10: RVU120: Highly selective and potent inhibitor of CDK8/19

    RVU120: Highly selective and potent inhibitor of CDK8/19 Small molecule, orally bioavailable RVU120: Potent/Selective → Targeted/Safer * • Low nM activity on CDK8/19: Predictions indicate near complete target engagement at clinically feasible drug exposure. • Excellent kinase selectivity: lack of bi

  11. Slide 11: RVU120 for Potential Treatment of Acute Myeloid Leukemia (AML)

    Slide 11: RVU120 for Potential Treatment of Acute Myeloid Leukemia (AML)

    RVU120 for Potential Treatment of Acute Myeloid Leukemia (AML) Preclinical Evidence: AML AML • Most common, highly aggressive CD34+ AML patient-derived xenografts: type of acute leukemia in adults Complete regression Hematologic recovery • Poor outcomes in most patients1 (peripheral blood) (bone mar

  12. Slide 12: DNMT3A and NPM1 are candidates for patient selection markers in AML

    Slide 12: DNMT3A and NPM1 are candidates for patient selection markers in AML

    DNMT3A and NPM1 are candidates for patient selection markers in AML DNMT3A/NPM1 mutated AML is dependent on dysregulation of HOX genes Loss of viability with RVU120 treatment • Low nM activity on CDK8/19: RVU120 reduces the viability of AML PDCs, in particular those bearing recurrent DNMT3A and NPM1

  13. Slide 13: Combination potential with venetoclax was shown in preclinical models

    Slide 13: Combination potential with venetoclax was shown in preclinical models

    Combination potential with venetoclax was shown in preclinical models Synergistic activity was demonstrated in venetoclax sensitive Synergy is driven by regulation of MCL-1: and venetoclax resistant models: RVU120 RVU120 Venetoclax sensitive cell line MCL-1 BCL-2 BCL-XL 4000 T u m o r v o lu m e , d

  14. Slide 14: RVU120: Phase I AML/MDS Study

    Slide 14: RVU120: Phase I AML/MDS Study

    RVU120: Phase I AML/MDS Study Recruitment in Part I ongoing 4 SITES IN US STUDY POPULATION: TREATMENT: Three-week cycle: Single oral dose of RVU120 every • Patients with other day for a total of 7 doses/cycle followed by relapsed/refractory AML or one week off high risk MDS • No upfront patient stra

  15. Slide 15: RVU120 Phase I: favorable safety and predictable PK in AML and HR-MDS patients

    Slide 15: RVU120 Phase I: favorable safety and predictable PK in AML and HR-MDS patients

    RVU120 Phase I: favorable safety and predictable PK in AML and HR-MDS patients Favorable safety profile of RVU120 in the first 19 treated patients Phase I Study in R/R AML and HR-MDS Data cutoff 11 November 2022 Most common* Treatment Emergent RVU120 (10-110 mg) Adverse Events (TEAE) Any grade n of

  16. Slide 16: RVU120 Phase I: early signs of efficacy in AML and HR-MDS

    Slide 16: RVU120 Phase I: early signs of efficacy in AML and HR-MDS

    RVU120 Phase I: early signs of efficacy in AML and HR-MDS ASH 2022: Data cut-off 11 November 2022 CLINICAL BENEFIT IN NINE PATIENTS: • A total of 19 patients have been treated with RVU120 through the data cut-off of November 11, 2022. • 16 patients had AML and 3 had HR- MDS. • All patients relapsed

  17. Slide 17: Patients with poor prognostic characteristics demonstrated clinical benefit with RVU120 treatment

    Slide 17: Patients with poor prognostic characteristics demonstrated clinical benefit with RVU120 treatment

    Patients with poor prognostic characteristics demonstrated clinical benefit with RVU120 treatment Dose PATIENT ID No. of prior MUTATIONAL PROFILE / KARYOTYPE Clinical activity (mg) (Diagnosis) regimens 100-003 (HR-MDS) 45, XY, add(5)(q22), der(6) 2 Marrow CR (77% BM Blast Reduction) 10 101-001 (AML)

  18. Slide 18: Hematological improvement was observed in three patients treated at 100 mg

    Slide 18: Hematological improvement was observed in three patients treated at 100 mg

    Hematological improvement was observed in three patients treated at 100 mg Pt 106-004 (100 mg) Pt 107-006 (100 mg) 200 200 165 150 1 7 .5 Recovery 150 Recovery 1 7 .5 150 of platelets 117 of platelets W BC , M O N, A NC, PLTS W B C , M O N , A N C , PLTS 100 100 H g b [g /d L ] H g b [g /d L ] 1 2 .

  19. Slide 19: Efficient CDK8 coverage by RVU120 results in erythroid responses

    Slide 19: Efficient CDK8 coverage by RVU120 results in erythroid responses

    Efficient CDK8 coverage by RVU120 results in erythroid responses in preclinical models and in patients RVU120 erythroid differentiation in CD34+ MDS patient-derived cells and in AML patient 106-004 Preclinical data (CD34+ MDS patient-derived cells) Clinical data (Patient 106-004) DMSO RVU120 PREDOSE

  20. Slide 20: Case Focus: AML patient achieved Complete Remission

    Slide 20: Case Focus: AML patient achieved Complete Remission

    Case Focus: AML patient achieved Complete Remission despite poor prognostics, including DNMT3A/NPM1 mutations Resolution of skin lesions: Patient • AML with mutations in FLT3, DNMT3A, NPM1 Characteristics • Failed 3 prior lines of therapy, including 2 FLT3 inhibitors and venetoclax + decitabine – kn

  21. Slide 21: Target engagement of >70% observed in patients treated with RVU120

    Slide 21: Target engagement of >70% observed in patients treated with RVU120

    Target engagement of >70 % has been observed in patients treated with RVU120 in a dose- and exposure-dependent manner Increasing concentrations and doses of RVU120 result in increasing pSTAT5 inhibition AML/ HR-MDS patients only: AML/ HR-MDS and solid tumor patients: • Target engagement can be track

  22. Slide 22: RVU120 in Solid Tumors

    Slide 22: RVU120 in Solid Tumors

    RVU120 in Solid Tumors Broad potential in solid tumors with strong preclinical evidence in TNBC Evidence in TNBC Solid • Preclinical evidence of activity RVU120 tested in subcutaneous xenograft of a TNBC cell line. Tumors across various solid tumors Tumor volume kinetics Body weight kinetics • Poten

  23. Slide 23: RVU120: Phase I/II Solid Tumor Study

    Slide 23: RVU120: Phase I/II Solid Tumor Study

    RVU120: Phase I/II Solid Tumor Study Recruitment in Part I ongoing STUDY POPULATION: TREATMENT: Three week cycle: Single oral dose of RVU120 every • Patients with r/r solid other day for a total of 7 doses/cycle followed by 2 SITES IN POLAND + 3 SITES IN SPAIN tumors progressing after at one week of

  24. Slide 24: Initial RVU120 Phase I data in solid tumors

    Slide 24: Initial RVU120 Phase I data in solid tumors

    Initial RVU120 Phase I data in solid tumors Disease stabilization in 4 out of 11 evaluable patients Treatment-emergent AEs: • The Phase I part included a heavily pretreated, unselected all- comer population. • 17 patients were treated at doses between 75 mg and 175 mg. • Disease stabilization was ac

  25. Slide 25: RVU120: Market Opportunity in AML

    Slide 25: RVU120: Market Opportunity in AML

    RVU120: Market Opportunity in AML Significant revenue growth in AML therapeutics Acute Myeloid Leukemia ~$1,300m Samples with mutation data (531 patients / 622 samples) AML Market1 ~$600m DNMT3A 2020 2025 $8.0 billion ~$500m DNMT3A $1.2 billion 46% + NPM1 ~30% ~$400m CAGR ~$300m NPM1 ~$300m RYVU CLI

  26. Slide 26: RVU120 Clinical Development and Commercialization strategy

    Slide 26: RVU120 Clinical Development and Commercialization strategy

    RVU120 Clinical Development and Commercialization strategy HEMATOLOGY CANCERS 2022 2023 2024 2025 2026 2027 2028 US Patient I II III IV I II III IV I II III IV I II III IV I II III IV I II III IV I II III IV Opportunity1 Fast-to-market strategy: Ph I Monotherapy RVU120 monotherapy 3,400+ Pivotal Ph

  27. Slide 27: RVU120: Acceleration of value creation in 2022 and beyond

    Slide 27: RVU120: Acceleration of value creation in 2022 and beyond

    RVU120: Acceleration of value creation in 2022 and beyond Leading with Science Clinical Trials Execution strategy Financial strength • Wholly owned, • Demonstrating proof-of- • Defined pathway to the • Cost-efficient first-in-class, selective oral concept, single-agent activity registration of RVU12

  28. Slide 28: SEL24 (MEN1703): First-in-Class PIM/FLT3 Inhibitor in AML

    Slide 28: SEL24 (MEN1703): First-in-Class PIM/FLT3 Inhibitor in AML

    SEL24 (MEN1703): First-in-Class PIM/FLT3 Inhibitor in AML

  29. Slide 29: SEL24 (MEN1703) – Summary

    Slide 29: SEL24 (MEN1703) – Summary

    SEL24 (MEN1703) – Summary Project licensed to Menarini Group, currently in Phase II clinical trials in AML Partnership agreement Proven safety Future with Menarini Group (2017) and therapeutic efficacy directions • PLN 20.3m upfront payment • Phase II partial clinical data (EHA2022) • Potential next

  30. Slide 30: SEL24 (MEN1703) showed single-agent efficacy in R/R AML patients

    Slide 30: SEL24 (MEN1703) showed single-agent efficacy in R/R AML patients

    SEL24 (MEN1703) showed single-agent efficacy in R/R AML patients, in particular in the IDH+ population, in the Dose Escalation/Cohort Expansion study Efficacy • Objective responses have been reported in 4 out of 48 patients (8%) • SEL24 (MEN1703) as a single agent across DE and CE phases, with 3 out

  31. Slide 31: Summary of recent progress in SEL24

    Slide 31: Summary of recent progress in SEL24

    Summary of recent progress in SEL24 2021 2022 2023 06/2021 / ASCO, EHA 06/2022 / ASCO, EHA • Manageable safety profile at the recommended dose Poster • Preliminary single agent efficacy in relapsed/refractory AML, • 25 patients enrolled in the IDHm cohort particularly in patients with IDH mutant dis

  32. Slide 32: Small Molecule Platform with Focus on Synthetic Lethality

    Slide 32: Small Molecule Platform with Focus on Synthetic Lethality

    Small Molecule Platform with Focus on Synthetic Lethality

  33. Slide 33: Integrated Discovery Engine at Ryvu

    Slide 33: Integrated Discovery Engine at Ryvu

    Integrated Discovery Engine at Ryvu TARGET IDENTIFICATION AND VALIDATION DRUG DISCOVERY RESEARCH PIPELINE ✓ Discovery of novel synthetic lethal target ✓ Integrated, multidisciplinary processes: ✓ Broad portfolio of synthetic lethal and pairs and actionable oncogenic drivers rapid lead identification

  34. Slide 34: Ryvu's Target Discovery Platform is focused on identification of novel synthetic lethal pairs

    Slide 34: Ryvu's Target Discovery Platform is focused on identification of novel synthetic lethal pairs

    Ryvu’s Target Discovery Platform is focused on identification of novel synthetic lethal pairs and oncogenic drivers INPUT DATA TARGET DISCOVERY PLATFORM PLATFORM OUTPUT CRISPR / shRNA Screens Novel Synthetic Lethalities Novel and Proprietary SL Targets Target #1 • Single-most synthetic lethal target

  35. Slide 35: Experimental target discovery platform – three approaches

    Slide 35: Experimental target discovery platform – three approaches

    Experimental target discovery platform – three approaches Experimental CRISPR-based target discovery platforms with the use of: Isogenic cell line pair Isogenic primary cells Patient-derived material Normal conditions Stress conditions MUT1 MUT2 MUT3 MUT4 Cellular stress in CRISPR screens tumor micr

  36. Slide 36: PRMT5 MTA-cooperative inhibitors

    Slide 36: PRMT5 MTA-cooperative inhibitors

    PRMT5 MTA-cooperative inhibitors PRMT5 SL INHIBITOR PROGRAM IN RYVU RYVU HAS SL PRMT5 INHIBITORS WITH THE BEST-IN-CLASS POTENTIAL PRMT5 MTA-cooperative inhibitors KEY RATIONALE exert synthetic lethal phenotype in MTAP deleted cells MECHANISM MRTX MTA-cooperative inhibitors 1719 RVU4 RVU5 RVU6 OF ACT

  37. Slide 37: Small molecule inhibitors of WRN

    Slide 37: Small molecule inhibitors of WRN

    Small molecule inhibitors of WRN WRN INHIBITORS OF ATPase ACTIVITY SELECTIVELY TARGETING TUMORS WRN INHIBITOR PROGRAM AT RYVU WITH MICROSATELLITE INSTABILITY Synthetic lethality of WRN 1 KEY RATIONALE Helicase function validated with microsatellite instability (MSI-high) in vitro as critical require

  38. Slide 38: BioNTech and Ryvu: Global Collaboration to Develop and Commercialize Immune Modulation Small Molecule Candidates

    Slide 38: BioNTech and Ryvu: Global Collaboration to Develop and Commercialize Immune Modulation Small Molecule Candidates

    BioNTech and Ryvu: Global Collaboration to Develop and Commercialize Immune Modulation Small Molecule Candidates Largest-ever Ryvu deal BioNTech is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. This collaboration leverages Ryvu’s small mole

  39. Slide 39: Exelixis and Ryvu: Exclusive License Agreement for STING Agonist-Based Therapies

    Slide 39: Exelixis and Ryvu: Exclusive License Agreement for STING Agonist-Based Therapies

    Exelixis and Ryvu: Exclusive License Agreement to Develop Novel STING Agonist-Based Targeted Cancer Therapies • In July 2022, Exelixis and Ryvu entered into an exclusive license agreement to expand Exelixis’ portfolio of biotherapeutics: Exelixis will combine Ryvu’s proprietary small molecule STING

  40. Slide 40: Corporate Progress

    Slide 40: Corporate Progress

    Corporate Progress

  41. Slide 41: Full-Year Financial Results: Q1 YTD 2023

    Slide 41: Full-Year Financial Results: Q1 YTD 2023

    Full-Year Financial Results: Q1 YTD 2023 Q1YTD Q1YTD $ million 2022* 2022* 2023* Cash position Revenues, incl.: 15.8 1.7 4.3 May 11, 2023 # of employees Partnering 8.7 0.0 2.9 Grants 6.6 1.6 1.3 $71.8M Total Costs**, incl.: 26.4 6.1 7.5 Clinical Pipeline 6.4 1.6 1.8 Available EIB Venture Debt Early

  42. Slide 42: EUR 22m venture debt obtained from the European Investment Bank

    Slide 42: EUR 22m venture debt obtained from the European Investment Bank

    EUR 22m venture debt obtained from the European Investment Bank Long-term financing for innovative growth companies: Instrument structure adapted to the business model Long-term financing repaid through bullet repayment, and remuneration independent of interest rates, partially secured by the Compan

  43. Slide 43: Business pipeline: 2023-2024 key goals and financing

    Slide 43: Business pipeline: 2023-2024 key goals and financing

    Ryvu’s Vision: From 2025, Ryvu will improve the lives of cancer patients Worldwide 2023-2024 KEY GOALS AND FINANCING ▪ Research funding from existing R&D collaborations ▪ RVU120 broad development ▪ Milestones from existing R&D collaborations ▪ New grant funding (including potential fast-to-market st

  44. Slide 44: Contact Data

    Slide 44: Contact Data

    CONTACT DATA: Ryvu Therapeutics S.A. www.ryvu.com ryvu@ryvu.com 44

Source: Internet Archive copy of ryvu.com

More decks from Ryvu Therapeutics SA

All 21 Ryvu Therapeutics SA decks